ABSTRACT
Orexin-A is a neuropeptide consisting of 33 amino acids with two intrachain disulfide bonds, namely Cys6-Cys12 and Cys7-Cys14, and is a potent stimulator of food consumption and gastric acid secretion. In contrast, orexin-B, a peptide containing 28 amino acids without disulfide bond, which has no stimulatory action of gastric acid. The objective of the present study was to characterize the receptor-mediated mechanism of orexin-A-induced stimulation of gastric acid secretion using orexin-A-related peptides with modification of disulfide bonds. Intracisternal injection of orexin-A, but not orexin-B or orexin-A (15-33), that does not contain both disulfide bonds stimulated gastric acid secretion in pylorus-ligated conscious rats. The ability of the stimulation of gastric acid output was less in three alanine-substituted orexin-A, [Ala(6,12)]orexin-A, [Ala(7,14)]orexin-A, and [Ala(6,7,12,14)]orexin-A, than orexin-A. Orexins-induced calcium increase was measured in CHO-K1 cells expressing OX1R or OX2R. Orexin-A induced a transient increase in [Ca(2+)]i in CHO-K1/OX1R cells in a dose-dependent manner. EC50 values for OX1R of orexin-A, orexin-B, or orexin-A (15-33) was 0.068, 0.69 or 4.1 nM, respectively, suggesting that peptides containing no disulfide bonds have lower potency for the receptor. Agonistic activity for OX1R of the three orexin-A analogues with modification of one or both disulfide bonds was significantly reduced as compared with that of orexin-A. EC50 values for OX2R of orexin-A and orexin-B was almost equal but potency for the receptor of orexin-A (15-33) and three alanine substituted orexin-A was less than that of orexin-A. A significant inverse relationship between gastric acid output and EC50 values for OX1R, but not OX2R, was observed. These results suggested that the orexin-A-induced acid stimulation requires OX1R activation and that disulfide bonds in orexin-A may have a key role in the receptor activation.
Subject(s)
Carrier Proteins/pharmacology , Disulfides , Gastric Acid/metabolism , Intracellular Signaling Peptides and Proteins , Neuropeptides/pharmacology , Receptors, Neuropeptide/metabolism , Amino Acid Sequence , Animals , CHO Cells , Calcium/metabolism , Carrier Proteins/metabolism , Cattle , Cricetinae , Dose-Response Relationship, Drug , Kinetics , Ligands , Male , Mice , Molecular Sequence Data , Neuropeptides/metabolism , Orexin Receptors , Orexins , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-CoupledABSTRACT
In the present study, we examine whether human pancreatic carcinoma cells express peroxisome proliferator-activated receptor gamma (PPARgamma) and the effect of PPARgamma activation by its selective ligand on cellular growth in pancreatic cancer cells. Immunohistochemical study of resected human pancreata using a polyclonal PPARgamma antibody revealed that PPARgamma protein expression in the nuclei of carcinoma cells was observed in 9 of 10 pancreatic adenocarcinomas. In contrast, normal pancreatic duct epithelial cells in the samples expressed no PPARgamma. Reverse transcription-PCR and Northern blot analysis demonstrated that all four tested human pancreatic cancer cell lines, PK-1, PK-8, PK-9, and MIA Paca-2, expressed PPARgamma mRNA. Luciferase assay in PK-1 cells showed that troglitazone, a selective ligand for PPARgamma, transactivated the transcription of a peroxisome proliferator response element-driven promoter in a dose-dependent fashion. Troglitazone inhibited the growth of all four pancreatic carcinoma cell lines in a dose-dependent manner. Cell cycle analysis by flow cytometry demonstrated that troglitazone induced G1 arrest in PK-1 cells. To examine the role of cyclin-dependent kinase inhibitors in the G1 arrest by troglitazone, we determined p27KiP1, p21CiP1/Waf1, or p18Ink4c protein expression by Western blot analysis in troglitazone-treated PK-1 cells. Troglitazone increased p27Kip1 but not p21Cip1/Waf1 or p18Inkc protein levels in time- and dose-dependent manners. To clarify the functional importance of p27Kip1 in the cell growth inhibition by troglitazone. All these results suggest that PPARgamma could be considered as a possible target molecule for treatment in human pancreatic carcinomas.
Subject(s)
Adenocarcinoma/pathology , Antineoplastic Agents/pharmacology , Cell Cycle Proteins , Chromans/pharmacology , Microtubule-Associated Proteins/biosynthesis , Pancreatic Neoplasms/pathology , Receptors, Cytoplasmic and Nuclear/physiology , Thiazoles/pharmacology , Thiazolidinediones , Transcription Factors/physiology , Tumor Suppressor Proteins , Adenocarcinoma/drug therapy , Adenocarcinoma/metabolism , Blotting, Northern , Cell Division/drug effects , Cyclin-Dependent Kinase Inhibitor p27 , G1 Phase/drug effects , Growth Inhibitors/pharmacology , Humans , Immunohistochemistry , Luciferases/genetics , Luciferases/metabolism , Microtubule-Associated Proteins/genetics , Oligonucleotides, Antisense/genetics , Oligonucleotides, Antisense/pharmacology , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/metabolism , Peroxisome Proliferators , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Cytoplasmic and Nuclear/biosynthesis , Receptors, Cytoplasmic and Nuclear/genetics , Response Elements/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors/biosynthesis , Transcription Factors/genetics , Troglitazone , Tumor Cells, CulturedABSTRACT
Recent study has indicated that cocaine-amphetamine-regulated transcript (CART) is an anorectic chemical in the brain. In the present study, we examined the hypothesis that CART may act in the central nervous system to alter gastric function. Food consumption, gastric acid secretion, and gastric emptying were measured after injection of CART into the cerebrospinal fluid in 24-h fasted Sprague Dawley rats. Central injection of CART inhibited food intake, gastric acid secretion, and gastric emptying. In contrast, ip injection of CART failed to inhibit gastric acid secretion and gastric emptying, suggesting that CART acts in the brain to suppress gastric acid secretion and gastric emptying. In the vagotomized animals, centrally administered CART did inhibit pentagastrin-stimulated gastric acid secretion. The CART-induced acid inhibition was also observed in rats treated with indomethacin, a cyclooxygenase inhibitor. In contrast, pretreatment with central administration of a CRF receptor antagonist, alpha-helical CRF9-41, completely blocked the central CART-induced inhibition of gastric acid secretion. All these results suggest that CART acts in the brain to inhibit gastric function via brain CRF system. The vagal pathway and the prostaglandin system are not involved in the acid inhibition.
Subject(s)
Brain/drug effects , Brain/physiology , Corticotropin-Releasing Hormone/physiology , Gastric Acid/metabolism , Nerve Tissue Proteins/pharmacology , Animals , Cyclooxygenase Inhibitors/pharmacology , Eating/drug effects , Gastric Emptying/drug effects , Gastric Juice/drug effects , Indomethacin/pharmacology , Kinetics , Male , Nerve Tissue Proteins/administration & dosage , Rats , Rats, Sprague-Dawley , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , VagotomySubject(s)
Cholecystitis/blood , Diabetes Mellitus, Type 2/blood , Leptin/blood , Acute Disease , Aged , C-Reactive Protein/metabolism , Cholecystitis/diagnosis , Diabetes Mellitus, Type 2/diagnosis , Diagnostic Imaging , Female , Humans , Systemic Inflammatory Response Syndrome/blood , Systemic Inflammatory Response Syndrome/diagnosisABSTRACT
It has been shown that intracerebroventricular injection of synthetic orexins stimulated food intake in rats. This pharmacological evidence suggests that orexins may have a role for the central regulation of feeding. In the present study, we investigated the hypothesis of whether endogenous orexins indeed play a vital role in feeding behavior. An anti-orexin polyclonal antibody was used throughout the study. First, we examined the specificity of the antibody to orexin by Western blot analysis and immunohistochemistry. Next, the effects of central injection of the orexin antibody on food intake in 24-h-fasted rats were evaluated. Western blot analysis revealed that the orexin antibody detected synthetic orexin-A. Immunohistochemical study showed that orexin-positive neurons were identified only in the lateral hypothalamic area, in agreement with previous reports. Neither control antibody nor the orexin antibody preabsorbed with excess amount of orexin-A detected neurons, indicating that the orexin antibody is specific. Intracisternal but not intraperitoneal injection of the orexin antibody dose-dependently suppressed feeding. All these results suggest that immunoneutralization of endogenous orexins in the brain reduced food intake. In other words, we suggest that endogenous brain orexin may have a physiologically relevant action on feeding behavior.
Subject(s)
Carrier Proteins/antagonists & inhibitors , Carrier Proteins/physiology , Eating/physiology , Intracellular Signaling Peptides and Proteins , Neuropeptides/antagonists & inhibitors , Neuropeptides/physiology , Animals , Antibodies/administration & dosage , Antibody Specificity , Carrier Proteins/immunology , Cisterna Magna , Hypothalamic Area, Lateral/metabolism , Immunoglobulin G/administration & dosage , Immunohistochemistry , Injections, Intraventricular , Male , Neuropeptides/immunology , Orexins , Rabbits , Rats , Rats, Sprague-DawleyABSTRACT
We investigated the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and the role of PPARgamma in cell growth in human gastric cancer cells. Reverse transcription-polymerase chain reaction, Northern blot and Western blot analyses showed that a human gastric cancer cell line, MKN45, expressed PPARgamma mRNA and protein. Luciferase assay in MKN45 cells showed that troglitazone, a selective ligand for PPARgamma, transactivated the transcription of a peroxisome proliferator response element-driven promoter. Troglitazone or pioglitazone, selective ligands for PPARgamma, inhibited the growth of MKN45 cells in a dose-dependent manner. Co-incubation of MKN45 cells with troglitazone induced DNA ladder formation. These results suggest that human gastric cancer cells express PPARgamma and that activation of PPARgamma inhibits cell growth and induces apoptosis in gastric cancer cells.
Subject(s)
Apoptosis , Cell Division , Receptors, Cytoplasmic and Nuclear/metabolism , Stomach Neoplasms/pathology , Transcription Factors/metabolism , Acyl-CoA Oxidase , Base Sequence , DNA Primers , Humans , Luciferases/genetics , Oxidoreductases/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Transcription Factors/geneticsABSTRACT
We measured serum leptin concentrations in 70 patients with diabetes mellitus to investigate the relationship between serum leptin levels and glycemic control. A positive correlation between serum leptin levels and body mass index or plasma insulin was obtained as reported previously. The present study also demonstrated an inverse association of serum leptin levels with hemoglobin A1c (HbA1c). Multiple regression analysis revealed that HbA1c was an independent determinant of serum leptin levels. These results suggest that HbA1c may be a factor to influence serum leptin levels and that hyperglycemia for a long period or poorly controlled diabetes may reduce leptin levels.
